Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab (MK-3475) Plus Bacillus Calmette-Guerin (BCG) in High-risk Non-muscle Invasive Bladder Cancer
NCT03711032Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Dec 2018
- Primary completion
- Jul 2028
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 30
01
Overview
A Phase 3 trial of pembrolizumab in bladder cancer, sponsored by Merck & Co.. Started Dec 2018; status: active, not recruiting.
02
Drugs
03
Conditions
bladder cancer
Beyond the preview
Go deeper on NCT03711032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03711032.